GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » H. Lundbeck AS (FRA:LDBB) » Definitions » Valuation Rank

H. Lundbeck AS (FRA:LDBB) Valuation Rank


View and export this data going back to 2022. Start your Free Trial

What is H. Lundbeck AS Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

H. Lundbeck AS Valuation Rank Related Terms

Thank you for viewing the detailed overview of H. Lundbeck AS's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

H. Lundbeck AS Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » H. Lundbeck AS (FRA:LDBB) » Definitions » Valuation Rank
Comparable Companies
OCSE:STENO ZTS XTER:MRK NSE:SUNPHARMA LSE:HLN TSE:4502 XSWX:GALD XTAE:TEVA XSWX:SDZ NSE:DIVISLAB HKSE:03692 SZSE:000538 NSE:TORNTPHARM VTRS BOM:500124 BOM:532321 TSE:4507 BOM:543904 BOM:500257 NBIX
Traded in Other Exchanges
HLBBF:USA HLUBF:USA HLUNBc:UK 0ABR:UK 0ND5:UK HLUN A:Denmark HLUN B:Denmark LUNB:Austria
Address
Ottiliavej 9, Valby, DNK, 2500
Website
https://www.lundbeck.com
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.